US2020261390A1PendingUtilityA1

Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma

Assignee: KOTHARI SHILPriority: Oct 28, 2015Filed: Apr 27, 2020Published: Aug 20, 2020
Est. expiryOct 28, 2035(~9.3 yrs left)· nominal 20-yr term from priority
A61K 31/05A61K 47/542A61P 3/00A61P 9/00A61K 31/198
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least one week.

Claims

exact text as granted — not AI-modified
1 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
 providing to the mammal in need thereof with a composition of 10 mg to 5000 mg daily of trans-resveratrol and arginine for at least one week.   
     
     
         2 . The method according to  claim 1 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition. 
     
     
         3 . The method according to  claim 1 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the conjugate. 
     
     
         4 . The method according to  claim 1 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal. 
     
     
         5 . The method according to  claim 1 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal. 
     
     
         6 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
 providing a mammal in need thereof with a composition of 10 mg to 5000 mg of a trans-resveratrol and arginine for at least two weeks.   
     
     
         7 . The method according to  claim 6 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition. 
     
     
         8 . The method according to  claim 6 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the composition. 
     
     
         9 . The method according to  claim 6 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal. 
     
     
         10 . The method according to  claim 6 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal. 
     
     
         11 . A method of increasing amounts of resveratrol in plasma levels of a mammal in need thereof, the method comprising:
 administering to a mammal in need thereof a composition of 10 mg to 5000 mg of a trans-resveratrol and arginine for at least one week, wherein the trans-resveratrol and arginine composition increases amounts of resveratrol in plasma levels of the mammal within at least 30 minutes of providing trans-resveratrol and arginine composition to the mammal.   
     
     
         12 . The method according to  claim 11 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 0.2 μM within about 30 minutes of providing the composition. 
     
     
         13 . The method according to  claim 11 , wherein the trans-resveratrol and arginine composition increases the plasma concentration of resveratrol of the mammal at least 1.6 μM within about one hour of providing the composition to the mammal. 
     
     
         14 . The method according to  claim 11 , wherein the trans-resveratrol and arginine composition provides 50 mg to 900 mg daily to the mammal. 
     
     
         15 . The method according to  claim 11 , wherein the trans-resveratrol and arginine composition provides 50 mg to 500 mg daily to the mammal.

Join the waitlist — get patent alerts

Track US2020261390A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.